Simultaneous Determination of Olanzapine, Risperidone and Paliperidone in Human Plasma by UPLC-MS/MS
10.6039/j.issn.1001-0408.2017.08.10
- VernacularTitle:UPLC-MS/MS法测定人血浆中奥氮平、利培酮和帕潘立酮的浓度
- Author:
Lichun FENG
;
Bohan YANG
;
Xueqin WANG
;
Qiang GUO
- Keywords:
Olanzapine;
Risperidone;
Paliperidone;
UPLC-MS/MS;
Plasma concentration
- From:
China Pharmacy
2017;28(8):1045-1048
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To develop a method for the concentration determination of olanzapine,risperidone and paliperidone in human plasma.METHODS:After liquid-liquid extraction,using buspirone hydrochloride as internal standard,the concentration of plasma sample was determined by UPLC-MS/MS.The determination was performed on ACQUITY UPLCTM BEH C18 column with mobile phase consisted of methanol-0.01 mol/L ammonium formate solution (gradient elution) at flow rate of 0.2 mL/min.The column temperature was 45 ℃,and sample size was 5 μL.The electrospray ionization source was adopted for positive ion scanning under MRM mode.Ion-pairs for quantitative analysis were as follows:m/z 313.29→256.25 (olanzapine),m/z 411.42→191.19 (ris peridone),m/z 427.45→207.18 (paliperidone) and m/z 386.43→122.37 (internal standard).RESULTS:The linear ranges of olanzapine,risperidone and paliperidone were 0.426-108.954,0.213-54.476,0.213-54.476 ng/mL,respectively.RSDs of inter-day and intra-day were all lower than 20%.The recoveries of them ranged 83.3%-112.9%,90.0%-109.8% and 95.2%-114.9%,respective ly.Extraction recoveries ranged 65.5%-95.0%,73.9%-98.5% and 73.6%-99.4%,respectively.Both plasma matrix effect and dilute effect didn't influence the determination of plasma concentration.The plasma concentrations of olanzapine,risperidone and paliperidone in 100 schizophrenia patients were (103.3 ± 73.6),(13.1 ± 13.1) and (23.2 ± 20.0) ng/mL,respectively.CONCLU SIONS:The method is simple,rapid,sensitive and specific.It can be used for the determination of plasma concentration and pharmacodynamic study of olanzapine,risperidone and paliperidone.